alexa Global Regulatory Best Practices: Companion Diagnostics | 19034
ISSN: 2167-7689

Pharmaceutical Regulatory Affairs: Open Access
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

4th International Conference on Pharmaceutical Regulatory Affairs

Abhishek Harde
ScientificTracks Abstracts: Pharmaceut Reg Affairs
DOI: 10.4172/2167-7689.S1.014
Abstract
Companion Diagnostics (CDxs) are commonly in vitro diagnostic (IVD) medical devices that detect a specific biomarker, related biomarkers, or a pattern of related biomarkers for a specific patient. CDxs are defined in the US, EU and Japan as follows US: A Companion Diagnostic (CDx) is defined by the U.S. FDA as an, ?in vitro diagnostic device that provides information that is essential for the safe and effective use of a corresponding therapeutic product.? EU: The IVD medical devices directive defines CDxs as the tests that are developed and/or used in direct combination with specific medicinal products or which are co-developed with newmedicinal products and may be used for the selection of patients suitable for therespective medication, for optimal and individualized dosing of medicinal products, for the exclusion of populations expected to suffer from severe adverse side effects and/or other medicinal products-related indications. Japan: The Pharmaceutical and Food Safety Bureau?s Evaluation and Licensing Division of the PMDA defines companion diagnostics as IVDs and medical devices used to 1) Identify patients more likely to respond to specified drugs such as molecular targeted therapies, 2) identify patients with a high risk of adverse reactions to these drugs, and 3) Optimize the administration and dosage regimen or determine when administration should be discontinued.
image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7